These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 12587355)

  • 21. Weight development in patients treated with risperidone: a 5-year naturalistic study.
    Neovius M; Eberhard J; Lindström E; Levander S
    Acta Psychiatr Scand; 2007 Apr; 115(4):277-85. PubMed ID: 17355518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.
    Singh MM; Kay SR
    Psychopharmacologia; 1975 Aug; 43(2):103-13. PubMed ID: 1103205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone-induced extrapyramidal reactions.
    Mahmood T; Clothier EB; Bridgman R
    Lancet; 1995 Nov; 346(8984):1226. PubMed ID: 7475677
    [No Abstract]   [Full Text] [Related]  

  • 24. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia.
    Molina-Ruiz AM; Pulpillo Á; Molina-Ruiz RM; Sagrario T; Requena L
    Int J Dermatol; 2016 Aug; 55(8):909-12. PubMed ID: 26340849
    [No Abstract]   [Full Text] [Related]  

  • 25. Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates.
    Gelder M; Kolakowska T
    Compr Psychiatry; 1979; 20(5):397-408. PubMed ID: 39704
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical studies of psychotropic drugs in pediatric patients].
    Wang X
    Zhonghua Hu Li Za Zhi; 1992 Aug; 27(8):340-2. PubMed ID: 1394728
    [No Abstract]   [Full Text] [Related]  

  • 27. Bioequivalency of generic and brand-named chlorpromazine.
    Simpson GM; Varga E; Reiss M; Cooper TB; Bergner PE; Lee JH
    Clin Pharmacol Ther; 1974 Jun; 15(6):631-41. PubMed ID: 4210298
    [No Abstract]   [Full Text] [Related]  

  • 28. Molindone and weight loss.
    Heikkinen H; Outakoski J; Meriläinen V; Tuomi A; Huttunen MO
    J Clin Psychiatry; 1993 Apr; 54(4):160-1. PubMed ID: 8486596
    [No Abstract]   [Full Text] [Related]  

  • 29. Biochemical versus psychopathological action profile of neuroleptics: a comparative study of chlorpromazine and oxypertine in acute psychotic disorders.
    van Praag HM; Dols LC; Schut T
    Compr Psychiatry; 1975; 16(3):255-63. PubMed ID: 237735
    [No Abstract]   [Full Text] [Related]  

  • 30. [Level of free and bound chlorpromazine fractions in the blood and urine during chlorpromazine treatment].
    Nurowska K; Szajbel W; Waszkiewicz E; Welbel L
    Psychiatr Pol; 1970; 4(4):435-42. PubMed ID: 5472581
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical psychometric evaluation of the effects of fluanxol, oxipertine and chlorpromazine in chronic schizophrenia. Comparative study].
    Predescu V; Ciurezu T; Romila A; Pirée S; Vianu I; Ionescu G; Braslă N; Florescu D; David E; Roman I; Zelingher R; Ivana D; Bucurică C; Damian N
    Neurol Psihiatr Neurochir; 1969; 14(5):389-400. PubMed ID: 5380156
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe extrapyramidal reaction due to risperidone in a case of neurofibromatosis.
    De León OA; Jobe TH; Furmaga KM; Gaviria M
    J Clin Psychiatry; 1997 Jul; 58(7):323. PubMed ID: 9269254
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of schizophrenia. Clinical pharmacological viewpoint].
    Sedvall G
    Lakartidningen; 1977 Jun; 74(22):2196-8. PubMed ID: 875529
    [No Abstract]   [Full Text] [Related]  

  • 34. [Changes in clinical course and symptomatology of schizophrenia following introduction of pharmacotherapy].
    Murakami K
    Seishin Shinkeigaku Zasshi; 1971 Aug; 73(8):635-49. PubMed ID: 5166836
    [No Abstract]   [Full Text] [Related]  

  • 35. [On peculiarities of the clinical picture and course of circular schizophrenia and the effect of active therapy on it].
    Barshteĭn EI; Eryshev OF
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(2):256-9. PubMed ID: 6000911
    [No Abstract]   [Full Text] [Related]  

  • 36. [Some forms of reaction to chlorpromazine in mentally retarded patients].
    Wasik A
    Psychiatr Pol; 1967; 1(1):91-4. PubMed ID: 5597276
    [No Abstract]   [Full Text] [Related]  

  • 37. Neuroleptic malignant syndrome.
    Br Med J (Clin Res Ed); 1983 Jul; 287(6385):128-9. PubMed ID: 6407706
    [No Abstract]   [Full Text] [Related]  

  • 38. Affective flattening, schizophrenia, and akinesia.
    Rifkin A
    Am J Psychiatry; 1980 Jan; 137(1):129. PubMed ID: 7352554
    [No Abstract]   [Full Text] [Related]  

  • 39. [Febrile states in schizophrenia following a paroxysmal course].
    Ermolina LA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1971; 71(5):731-6. PubMed ID: 5122136
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of long-term therapy with aminazin on the structure and function of the liver].
    Avrutskiĭ GIa; Gurovich IIa; Romanov IuD; Khmelevskiĭ DL; Mukhin AS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(7):1050-5. PubMed ID: 5077762
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.